PRESS RELEASES

PRESS RELEASES

October 15, 2018
BELGRADE, MT , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the appointment of Michael Mainelli to serve as Interim Chief Executive
August 20, 2018
BELGRADE, MT , Aug. 20, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings , Inc. (NYSE American: XTNT), a leader in the development and commercialization of regenerative medicine products and medical devices, today announced the appointment of Kathie Lenzen as chief financial officer, effective
August 7, 2018
BELGRADE, MT , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings , Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported financial and operating results for the second quarter ended June 30, 2018 .
August 6, 2018
BELGRADE, MT , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announces that it will release its financial results for the quarter ended June 30, 2018 , after the close of
July 10, 2018
BELGRADE, MT , July 10, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Kevin Brandt to the new executive position of Chief Commercial Officer effective
June 19, 2018

BELGRADE, MT , June 19, 2018 (GLOBE NEWSWIRE) -- Xtant TM Medical Holdings, Inc. (NYSE American: XTNT) announces that the subscription period for its previously announced rights offering (the “Offering”) of shares of the Company’s common stock at a subscription price of $7.20 per share expired on

May 2, 2018
BELGRADE, MT / ACCESSWIRE / May 2, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the quarter ended March 31, 2018, after the close of the